“Life is short compared to the sun”
Life is too short compared to the sun.
To improve quality of life and find happiness, we must be free from illness.
But,
Every year, 18 million people worldwide lose their lives from cardiovascular
and cerebrovascular diseases, and 55 million people suffer from dementia. (WHO data)
The longevity factor HDL is the new key to preventing cardiovascular and cerebrovascular diseases as well as dementia.
HDL can prevent myocardial infarction, angina, stroke, dementia, and peripheral vascular diseases
by preventing the narrowing or blockage of blood vessels.
Just as HBM (High Bandwidth Memory) has revolutionized data transfer speeds,
enhancing the capabilities of AI (Artificial Intelligence) and playing a pivotal role in the birth of generative AI (such as Chat GPT),
HDL (High Density Lipoprotein) keeps blood vessels healthy and promotes good blood flow,
thereby aiding the enhancement of human intelligence (HI).
The "Longevity Factor HDL Symposium" is an international symposium
organized by YTN Science and mainly sponsored by RAYDEL.
This symposium aims to explore significant studies on HDL and various methods
to increase the quantity and functionality of the longevity factor HDL,
with the goal of preventing disease and improving health.
We would like to invite leading HDL researchers from around the world
to explore ways to enhance human health and quality of life through HDL.
Life is too short compared to the sun.
To improve quality of life and find happiness, we must be free from illness.
But,
Every year, 18 million people worldwide lose their lives from cardiovascular
and cerebrovascular diseases, and 55 million people suffer from dementia. (WHO data)
The longevity factor HDL is the new key to preventing cardiovascular and cerebrovascular diseases as well as dementia.
HDL can prevent myocardial infarction, angina, stroke, dementia, and peripheral vascular diseases
by preventing the narrowing or blockage of blood vessels.
Just as HBM (High Bandwidth Memory) has revolutionized data transfer speeds,
enhancing the capabilities of AI (Artificial Intelligence) and playing a pivotal role in the birth of generative AI (such as Chat GPT),
HDL (High Density Lipoprotein) keeps blood vessels healthy and promotes good blood flow,
thereby aiding the enhancement of human intelligence (HI).
The "Longevity Factor HDL Symposium" is an international symposium
organized by YTN Science and mainly sponsored by RAYDEL.
This symposium aims to explore significant studies on HDL and various methods
to increase the quantity and functionality of the longevity factor HDL,
with the goal of preventing disease and improving health.
We would like to invite leading HDL researchers from around the world
to explore ways to enhance human health and quality of life through HDL.
“Life is short compared to the sun”
Life is too short compared to the sun.
To improve quality of life and find happiness, we must be free from illness.
But,
Every year, 18 million people worldwide lose their lives from cardiovascular
and cerebrovascular diseases, and 55 million people suffer from dementia. (WHO data)
The longevity factor HDL is the new key to preventing cardiovascular and cerebrovascular diseases as well as dementia.
HDL can prevent myocardial infarction, angina, stroke, dementia, and peripheral vascular diseases
by preventing the narrowing or blockage of blood vessels.
Just as HBM (High Bandwidth Memory) has revolutionized data transfer speeds,
enhancing the capabilities of AI (Artificial Intelligence) and playing a pivotal role in the birth of generative AI (such as Chat GPT),
HDL (High Density Lipoprotein) keeps blood vessels healthy and promotes good blood flow,
thereby aiding the enhancement of human intelligence (HI).
The "Longevity Factor HDL Symposium" is an international symposium
organized by YTN Science and mainly sponsored by RAYDEL.
This symposium aims to explore significant studies on HDL and various methods
to increase the quantity and functionality of the longevity factor HDL,
with the goal of preventing disease and improving health.
We would like to invite leading HDL researchers from around the world
to explore ways to enhance human health and quality of life through HDL.
Life is too short compared to the sun.
To improve quality of life and find happiness, we must be free from illness.
But,
Every year, 18 million people worldwide lose their lives from cardiovascular
and cerebrovascular diseases, and 55 million people suffer from dementia. (WHO data)
The longevity factor HDL is the new key to preventing cardiovascular and cerebrovascular diseases as well as dementia.
HDL can prevent myocardial infarction, angina, stroke, dementia, and peripheral vascular diseases
by preventing the narrowing or blockage of blood vessels.
Just as HBM (High Bandwidth Memory) has revolutionized data transfer speeds,
enhancing the capabilities of AI (Artificial Intelligence) and playing a pivotal role in the birth of generative AI (such as Chat GPT),
HDL (High Density Lipoprotein) keeps blood vessels healthy and promotes good blood flow,
thereby aiding the enhancement of human intelligence (HI).
The "Longevity Factor HDL Symposium" is an international symposium
organized by YTN Science and mainly sponsored by RAYDEL.
This symposium aims to explore significant studies on HDL and various methods
to increase the quantity and functionality of the longevity factor HDL,
with the goal of preventing disease and improving health.
We would like to invite leading HDL researchers from around the world
to explore ways to enhance human health and quality of life through HDL.
The Speakers
- Kerry-Anne Rye, Ph.D.
- Professor, Deputy Head, School of Biomedical Sciences, UNSW Sydney (AU)
· 2022-present: Deputy Head, School of Biomedical Sciences, UNSW Sydney
· 2016-2022: Deputy Head (Research), School of Medical Sciences, UNSW Sydney
· 2013-2015: Acting Director, Centre for Vascular Research, Faculty of Medicine, UNSW Sydney
· 2005-2012: Associate Director, The Heart Research Institute, Sydney
· 2002-2006: Principal Research Fellow, National Heart Foundation of Australia
· 1999-2001: Senior Career Research Fellow, National Heart Foundation of Australia
- Laura Calabresi, Ph.D.
- Professor, Pharmacology, Department of Pharmacological and Biomolecular Sciences, University of Milano (ITA)
· 2023-present: President of the Managing Committee, Faculty of Pharmacy, University of Milano
· 2021-present: Editor-in-chief of Atherosclerosis Plus
· 2016-present: Full Professor of Pharmacology, University of Milano
· 2015-present: Scientific Coordinator of the Center E. Grossi Paoletti, University of Milano
· 2016-2021: Head of the master program in Pharmaceutical Biotechnology, University of Milan
- Takuji Shirasawa, M.D., Ph.D.
- President of Shirasawa Anti-Aging Medical Institute, Director of International Preventive Medical Association (JP)
· 2012-present: President, Shirasawa Anti-Aging Medical Institute
· 2013-present: Director, Japan Anti-Aging Food Association
· 2015-present Visiting Professor, University of Michigan, Neurology
· 2017-present: Director at Ochanomizu Longevity & Health Clinic
· 2021-present: Director, International Preventive Medical Association
- Anand Rohatgi, M.D.
- Professor, Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center (US)
· 2021 - present: Professor, Internal Medicine, Division of Cardiology, UT Southwestern Medical Center
· 2018 – present: Associate Program Director of Cardiovascular Fellowship
· 2009-present: Fellow of the American College of Cardiology
· 2013-present: Fellow of the American Heart Association
· (present) Lancet, JAMA, AHA, etc., Reviewer of multiple journals
- Keijiro Saku, M.D., Ph.D.
- President of Kietsukal NAKAGAWA Hospital, President Emeritus, Fukuoka University (JP)
· 2023 ~present:President Emeritus, Fukuoka University
· 2019 ~ 2023: President, Fukuoka University
· 2013-2019: Dean, Fukuoka Univ. Faculty of Medicine, Fukuoka,
· 2000～2017: Professor and Chairman, Department of Cardiology, Fukuoka Univ. School of Medicine
· 2024-president: President,Tobacco Control Medical-Dental Research Network
· present: President, Social Media Corporation Kietsukai Nakagawa Hospital
- Theodoros Kelesidis, Ph.D.
- Associate Professor, Department of Medicine, Division of Infectious Diseases, UT Southwestern Medical Center (US)
· 2023-present: Associate Professor, Department of Medicine, Division of Infectious Diseases, UT Southwestern Medical Center
· 2023-present: Associate Editor Infectious Agents and Disease, Frontiers in Microbiology
· 2019-2023: Associate Professor, Division of Infectious Diseases, David Geffen School of Medicine at University of California Los Angeles
· 2007-2009 Research Fellow, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School
· (present) Member of American Heart Association, International AIDS Society
- Sarahi Mendoza Castaño, Ph.D.
- Director of Research, Development and Innovation. National Center for Scientific Research(CUB)
· Ph.D., University of Havana, Pharmaceutical Sciences
· Head of the Quality Assurance Unit at the Center of Natural Products of the National Center for Scientific Research
· Head of the Quality Assurance Unit of Laboratorios Dalmer, SA.
· Head of Centre of Natural Products, National Centre for Scientific Research.
- Kyung Hyun Cho, Ph.D.
- Head of RAYDEL Research Institute (KOR)
· 2021-present: Head, RAYDEL Research Institute
· 2019 - 2021: Head, Korea Research Institute of Lipoproteins
· 2014.3- 2019 : Yeungnam University, Dept of Medical Biotechnology, Full professor
· 2013. 9- 2019: Head, BK21plus Serum Biomedical Research and Education Team
· Guest Editor, special issue of HDL metabolism and functionality in Molecules and IJMS journal
The Speakers
-
- Kerry-Anne Rye, Ph.D.
- Professor, Deputy Head, School of Biomedical Sciences, UNSW Sydney (AU)
· 2022-present: Deputy Head, School of Biomedical Sciences, UNSW Sydney
· 2016-2022: Deputy Head (Research), School of Medical Sciences, UNSW Sydney
· 2013-2015: Acting Director, Centre for Vascular Research, Faculty of Medicine, UNSW Sydney
· 2005-2012: Associate Director, The Heart Research Institute, Sydney
· 2002-2006: Principal Research Fellow, National Heart Foundation of Australia
· 1999-2001: Senior Career Research Fellow, National Heart Foundation of Australia
-
- Laura Calabresi, Ph.D.
- Professor, Pharmacology, Department of Pharmacological and Biomolecular Sciences, University of Milano (ITA)
· 2023-present: President of the Managing Committee, Faculty of Pharmacy, University of Milano
· 2021-present: Editor-in-chief of Atherosclerosis Plus
· 2016-present: Full Professor of Pharmacology, University of Milano
· 2015-present: Scientific Coordinator of the Center E. Grossi Paoletti, University of Milano
· 2016-2021: Head of the master program in Pharmaceutical Biotechnology, University of Milan
-
- Takuji Shirasawa, M.D., Ph.D.
- President of Shirasawa Anti-Aging Medical Institute, Director of International Preventive Medical Association (JP)
· 2012-present: President, Shirasawa Anti-Aging Medical Institute
· 2013-present: Director, Japan Anti-Aging Food Association
· 2015-present Visiting Professor, University of Michigan, Neurology
· 2017-present: Director at Ochanomizu Longevity & Health Clinic
· 2021-present: Director, International Preventive Medical Association
-
- Anand Rohatgi, M.D.
- Professor, Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center (US)
· 2021 - present: Professor, Internal Medicine, Division of Cardiology, UT Southwestern Medical Center
· 2018 – present: Associate Program Director of Cardiovascular Fellowship
· 2009-present: Fellow of the American College of Cardiology
· 2013-present: Fellow of the American Heart Association
· (present) Lancet, JAMA, AHA, etc., Reviewer of multiple journals
-
- Keijiro Saku, M.D., Ph.D.
- President of Kietsukal NAKAGAWA Hospital, President Emeritus, Fukuoka University (JP)
· 2023 ~present:President Emeritus, Fukuoka University
· 2019 ~ 2023: President, Fukuoka University
· 2013-2019: Dean, Fukuoka Univ. Faculty of Medicine, Fukuoka,
· 2000～2017: Professor and Chairman, Department of Cardiology, Fukuoka Univ. School of Medicine
· 2024-president: President,Tobacco Control Medical-Dental Research Network
· present: President, Social Media Corporation Kietsukai Nakagawa Hospital
-
- Theodoros Kelesidis, Ph.D.
- Associate Professor, Department of Medicine, Division of Infectious Diseases, UT Southwestern Medical Center (US)
· 2023-present: Associate Professor, Department of Medicine, Division of Infectious Diseases, UT Southwestern Medical Center
· 2023-present: Associate Editor Infectious Agents and Disease, Frontiers in Microbiology
· 2019-2023: Associate Professor, Division of Infectious Diseases, David Geffen School of Medicine at University of California Los Angeles
· 2007-2009 Research Fellow, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School
· (present) Member of American Heart Association, International AIDS Society
-
- Sarahi Mendoza Castaño, Ph.D.
- Director of Research, Development and Innovation. National Center for Scientific Research(CUB)
· Ph.D., University of Havana, Pharmaceutical Sciences
· Head of the Quality Assurance Unit at the Center of Natural Products of the National Center for Scientific Research
· Head of the Quality Assurance Unit of Laboratorios Dalmer, SA.
· Head of Centre of Natural Products, National Centre for Scientific Research.
-
- Kyung Hyun Cho, Ph.D.
- Head of RAYDEL Research Institute (KOR)
· 2021-present: Head, RAYDEL Research Institute
· 2019 - 2021: Head, Korea Research Institute of Lipoproteins
· 2014.3- 2019 : Yeungnam University, Dept of Medical Biotechnology, Full professor
· 2013. 9- 2019: Head, BK21plus Serum Biomedical Research and Education Team
· Guest Editor, special issue of HDL metabolism and functionality in Molecules and IJMS journal
Locations
Grand Hyatt Seoul
322, Sowol-ro, Yongsan-gu, Seoul, Republic of Korea Grand Salon
Related Inquiries
e-mail: pr@raydel.co.kr
T: +82-070-4830-6912
